1. Home
  2. ANGI vs ANAB Comparison

ANGI vs ANAB Comparison

Compare ANGI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANGI
  • ANAB
  • Stock Information
  • Founded
  • ANGI 1995
  • ANAB 2005
  • Country
  • ANGI United States
  • ANAB United States
  • Employees
  • ANGI N/A
  • ANAB N/A
  • Industry
  • ANGI Advertising
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANGI Consumer Discretionary
  • ANAB Health Care
  • Exchange
  • ANGI Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • ANGI 566.2M
  • ANAB 621.1M
  • IPO Year
  • ANGI 2017
  • ANAB 2017
  • Fundamental
  • Price
  • ANGI $16.06
  • ANAB $27.06
  • Analyst Decision
  • ANGI Hold
  • ANAB Buy
  • Analyst Count
  • ANGI 8
  • ANAB 10
  • Target Price
  • ANGI $20.33
  • ANAB $44.25
  • AVG Volume (30 Days)
  • ANGI 1.3M
  • ANAB 515.5K
  • Earning Date
  • ANGI 08-05-2025
  • ANAB 08-04-2025
  • Dividend Yield
  • ANGI N/A
  • ANAB N/A
  • EPS Growth
  • ANGI N/A
  • ANAB N/A
  • EPS
  • ANGI 1.03
  • ANAB N/A
  • Revenue
  • ANGI $1,125,635,000.00
  • ANAB $111,872,000.00
  • Revenue This Year
  • ANGI N/A
  • ANAB N/A
  • Revenue Next Year
  • ANGI $4.24
  • ANAB $24.39
  • P/E Ratio
  • ANGI $15.57
  • ANAB N/A
  • Revenue Growth
  • ANGI N/A
  • ANAB 387.20
  • 52 Week Low
  • ANGI $10.88
  • ANAB $12.21
  • 52 Week High
  • ANGI $29.15
  • ANAB $41.31
  • Technical
  • Relative Strength Index (RSI)
  • ANGI 51.50
  • ANAB 70.24
  • Support Level
  • ANGI $16.00
  • ANAB $23.10
  • Resistance Level
  • ANGI $17.13
  • ANAB $26.17
  • Average True Range (ATR)
  • ANGI 0.64
  • ANAB 1.33
  • MACD
  • ANGI 0.02
  • ANAB 0.27
  • Stochastic Oscillator
  • ANGI 48.06
  • ANAB 100.00

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: